Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study

Michael  Dreher; David Price; Asparuh Gardev; Pascale  Peeters; Satish  Arora; Simone  van der Sar-van der Brugge; Richard Dekhuijzen; Omar S Usmani

doi:10.1177/1479973120986228

Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study

Michael Dreher^* (Corresponding Author), David Price, Asparuh Gardev, Pascale Peeters, Satish Arora, Simone van der Sar-van der Brugge, Richard Dekhuijzen, Omar S Usmani

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

10 Downloads (Pure)

Abstract

Objectives
The Respimat® Soft MistTM inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction and preference with the re-usable device.
Methods
This 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) naïve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire.
Results
In total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious.
Discussion
This study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient’s prior experience with this inhaler.

Original language	English
Pages (from-to)	1-10
Number of pages	10
Journal	Chronic Respiratory Disease
Volume	18
Early online date	1 Feb 2021
DOIs	https://doi.org/10.1177/1479973120986228
Publication status	Published - 2021

Bibliographical note

Acknowledgements:
Medical writing assistance, in the form of the preparation and revision of the manuscript, was supported financially by Boehringer Ingelheim and provided by Paul Todd, PhD, at MediTech Media, UK under the authors’ conceptual direction and based on feedback from the authors.
Funding:
Support for this project, medical writing support and in the study and collection, analysis, and interpretation of data was provided by Boehringer Ingelheim International GmBH.

Keywords

COPD
Respimat
switch
preference
PASAPQ
ease of handling

Access to Document

10.1177/1479973120986228Licence: CC BY

Dreher_et_al_CRD_PatientPerceptionsOfThe_VoR
https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Final published version, 827 KBLicence: CC BY

Cite this

Dreher, M., Price, D., Gardev, A., Peeters, P., Arora, S., van der Sar-van der Brugge, S., Dekhuijzen, R., & Usmani, O. S. (2021). Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study. Chronic Respiratory Disease, 18, 1-10. https://doi.org/10.1177/1479973120986228

Dreher, M, Price, D, Gardev, A, Peeters, P, Arora, S, van der Sar-van der Brugge, S, Dekhuijzen, R & Usmani, OS 2021, 'Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study', Chronic Respiratory Disease, vol. 18, pp. 1-10. https://doi.org/10.1177/1479973120986228

@article{6481533409df4ebaabdb77543bbd9695,

title = "Patient perceptions of the re-usable Respimat{\textregistered} Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study",

abstract = "ObjectivesThe Respimat{\textregistered} Soft MistTM inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction and preference with the re-usable device.MethodsThis 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) na{\"i}ve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire.ResultsIn total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were {\textquoteleft}satisfied{\textquoteright} or {\textquoteleft}very satisfied{\textquoteright} with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious.DiscussionThis study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient{\textquoteright}s prior experience with this inhaler. ",

keywords = "COPD, Respimat, switch, preference, PASAPQ, ease of handling",

author = "Michael Dreher and David Price and Asparuh Gardev and Pascale Peeters and Satish Arora and {van der Sar-van der Brugge}, Simone and Richard Dekhuijzen and Usmani, {Omar S}",

note = "Acknowledgements: Medical writing assistance, in the form of the preparation and revision of the manuscript, was supported financially by Boehringer Ingelheim and provided by Paul Todd, PhD, at MediTech Media, UK under the authors{\textquoteright} conceptual direction and based on feedback from the authors. Funding: Support for this project, medical writing support and in the study and collection, analysis, and interpretation of data was provided by Boehringer Ingelheim International GmBH. ",

year = "2021",

doi = "10.1177/1479973120986228",

language = "English",

volume = "18",

pages = "1--10",

journal = "Chronic Respiratory Disease",

issn = "1479-9723",

publisher = "Sage Publications",

}

TY - JOUR

T1 - Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device

T2 - a real-world, non-interventional COPD study

AU - Dreher, Michael

AU - Price, David

AU - Gardev, Asparuh

AU - Peeters, Pascale

AU - Arora, Satish

AU - van der Sar-van der Brugge, Simone

AU - Dekhuijzen, Richard

AU - Usmani, Omar S

N1 - Acknowledgements: Medical writing assistance, in the form of the preparation and revision of the manuscript, was supported financially by Boehringer Ingelheim and provided by Paul Todd, PhD, at MediTech Media, UK under the authors’ conceptual direction and based on feedback from the authors. Funding: Support for this project, medical writing support and in the study and collection, analysis, and interpretation of data was provided by Boehringer Ingelheim International GmBH.

PY - 2021

Y1 - 2021

N2 - ObjectivesThe Respimat® Soft MistTM inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction and preference with the re-usable device.MethodsThis 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) naïve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire.ResultsIn total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious.DiscussionThis study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient’s prior experience with this inhaler.

AB - ObjectivesThe Respimat® Soft MistTM inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction and preference with the re-usable device.MethodsThis 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) naïve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire.ResultsIn total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious.DiscussionThis study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient’s prior experience with this inhaler.

KW - COPD

KW - Respimat

KW - switch

KW - preference

KW - PASAPQ

KW - ease of handling

UR - http://www.scopus.com/inward/record.url?scp=85100565993&partnerID=8YFLogxK

U2 - 10.1177/1479973120986228

DO - 10.1177/1479973120986228

M3 - Article

C2 - 33522304

SN - 1479-9723

VL - 18

SP - 1

EP - 10

JO - Chronic Respiratory Disease

JF - Chronic Respiratory Disease

ER -

Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this